New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

The results presented here show that inhibition ... mice. These results indicate that continuous hTERT activity is required for the maintenance of the malignant growth phenotype of many tumor ...

Glycolysis is a central metabolic pathway by which cells obtain energy from sugar. Cancer cells in particular have long been thought to depend on the energy obtained through glycolysis, a phenomenon ...

The therapy performed well in mice, activating tumor suppressor genes and impairing tumor growth. Because UHFR1 is implicated as an oncogene in numerous ... Defining ortholog-specific UHRF1 inhibition ...

showing a resistance to subsequent D2-induced cell growth inhibition. Three tumor-bearing mouse models with U251, NCI-H446 or S180 tumor cells were used to confirm that pre-exposure of tumor-bearing ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment ...

When they delivered the Cas13 package into tumor microenvironments in mice, they found that it silenced those immune suppression genes (essentially un-silencing or re-activating the immune system ...

Researchers have now developed a new approach that simultaneously targets several of these pro-tumor actions at once, which they have demonstrated can effectively reduce tumor growth across ...